These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 7514856)

  • 21. Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine.
    Martin JL; Wilson JE; Haynes RL; Furman PA
    Proc Natl Acad Sci U S A; 1993 Jul; 90(13):6135-9. PubMed ID: 7687061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structures of ternary complexes of rat DNA polymerase beta, a DNA template-primer, and ddCTP.
    Pelletier H; Sawaya MR; Kumar A; Wilson SH; Kraut J
    Science; 1994 Jun; 264(5167):1891-903. PubMed ID: 7516580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.
    Kleim JP; Rösner M; Winkler I; Paessens A; Kirsch R; Hsiou Y; Arnold E; Riess G
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):34-8. PubMed ID: 8552634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture.
    Larder BA; Coates KE; Kemp SD
    J Virol; 1991 Oct; 65(10):5232-6. PubMed ID: 1716689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals.
    Brindeiro R; Vanderborght B; Caride E; Correa L; Oravec RM; Berro O; Stuyver L; Tanuri A
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1674-80. PubMed ID: 10390221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
    Foli A; Sogocio KM; Anderson B; Kavlick M; Saville MW; Wainberg MA; Gu Z; Cherrington JM; Mitsuya H; Yarchoan R
    Antiviral Res; 1996 Oct; 32(2):91-8. PubMed ID: 8891168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
    Gao Q; Gu Z; Parniak MA; Cameron J; Cammack N; Boucher C; Wainberg MA
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1390-2. PubMed ID: 8392313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH; Martin JL; Tudor-Williams G; Bach MC; Vavro CL; King DM; Kellam P; Kemp SD; Larder BA
    Science; 1991 Sep; 253(5027):1557-9. PubMed ID: 1716788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
    Das K; Martinez SE; Arnold E
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
    Iversen AK; Shafer RW; Wehrly K; Winters MA; Mullins JI; Chesebro B; Merigan TC
    J Virol; 1996 Feb; 70(2):1086-90. PubMed ID: 8551567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
    Anderson KS
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
    García-Lerma JG; Nidtha S; Heneine W
    J Infect Dis; 2001 Aug; 184(4):507-10. PubMed ID: 11471110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
    Harrigan PR; Kinghorn I; Bloor S; Kemp SD; Nájera I; Kohli A; Larder BA
    J Virol; 1996 Sep; 70(9):5930-4. PubMed ID: 8709214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
    Sharma PL; Chatis PA; Dogon AL; Mayers DL; McCutchan FE; Page C; Crumpacker CS
    Virology; 1996 Sep; 223(2):365-9. PubMed ID: 8806572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene.
    Gu Z; Gao Q; Fang H; Parniak MA; Brenner BG; Wainberg MA
    Leukemia; 1994 Apr; 8 Suppl 1():S166-9. PubMed ID: 7512178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates.
    Ueno T; Shirasaka T; Mitsuya H
    J Biol Chem; 1995 Oct; 270(40):23605-11. PubMed ID: 7559526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.
    García-Lerma JG; Gerrish PJ; Wright AC; Qari SH; Heneine W
    J Virol; 2000 Oct; 74(20):9339-46. PubMed ID: 11000201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.
    Naeger LK; Margot NA; Miller MD
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2179-84. PubMed ID: 12069972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.
    Shirasaka T; Kavlick MF; Ueno T; Gao WY; Kojima E; Alcaide ML; Chokekijchai S; Roy BM; Arnold E; Yarchoan R
    Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2398-402. PubMed ID: 7534421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.
    Lacey SF; Larder BA
    J Virol; 1994 May; 68(5):3421-4. PubMed ID: 7512165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.